Ginger J. Gardner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ginger J. Gardner has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Oliver Zivanovic
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
14 shared publications- Dennis S. Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA
11 shared publications Kara Long Roche
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
9 shared publications- Mario M. Leitao
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA
9 shared publications - Yukio Sonoda
Memorial Sloan Kettering Cancer Center
9 shared publications - Kara Long Roche
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
8 shared publications
Latest Publications
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600005
Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery
PURPOSE: Patients undergoing cancer surgery often face complex, multidisciplinary needs related to recovery and discharge. The aim of this study was to develop and assess the adoption of an electronic patient-reported outcomes (ePRO) tool, Goals to Discharge (G2D), to improve discharge planning and recovery following colorectal and thoracic cancer surgeries. METHODS: We developed the G2D tool using a mixed-methods approach incorporating feedback from patients, clinicians, and stakeholders. Survey items were selected through a stepwise process aligned with Enhanced Recovery After Surgery pathways. Hospitalized patients recovering from colorectal or thoracic surgeries at a tertiary cancer center were prompted to complete the G2D tool on postoperative day 1 until discharge. Adoption factors were analyzed for associations with patient engagement and postoperative length of stay (LOS). RESULTS: Among 3,878 patients, the G2D tool had an adoption rate of 31% (1,190 patients with at least 1 survey response). Factors such as age, American Society of Anesthesia (ASA) score, primary language, and prolonged recovery room stays influenced adoption. Respondents to the G2D tool had a 3.7% reduction in the risk of prolonged LOS compared with nonrespondents ([95% CI, 0.84 to 6.5]; P = .011). CONCLUSION: The G2D ePRO tool enhanced communication between patients and clinical teams, contributing to improved discharge planning and recovery. Respondents to the tool had a significantly lower risk of prolonged hospital stays after surgery. Further research is needed to refine digital discharge tools and explore strategies for optimizing recovery preparation.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600005
Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery
PURPOSE: Patients undergoing cancer surgery often face complex, multidisciplinary needs related to recovery and discharge. The aim of this study was to develop and assess the adoption of an electronic patient-reported outcomes (ePRO) tool, Goals to Discharge (G2D), to improve discharge planning and recovery following colorectal and thoracic cancer surgeries. METHODS: We developed the G2D tool using a mixed-methods approach incorporating feedback from patients, clinicians, and stakeholders. Survey items were selected through a stepwise process aligned with Enhanced Recovery After Surgery pathways. Hospitalized patients recovering from colorectal or thoracic surgeries at a tertiary cancer center were prompted to complete the G2D tool on postoperative day 1 until discharge. Adoption factors were analyzed for associations with patient engagement and postoperative length of stay (LOS). RESULTS: Among 3,878 patients, the G2D tool had an adoption rate of 31% (1,190 patients with at least 1 survey response). Factors such as age, American Society of Anesthesia (ASA) score, primary language, and prolonged recovery room stays influenced adoption. Respondents to the G2D tool had a 3.7% reduction in the risk of prolonged LOS compared with nonrespondents ([95% CI, 0.84 to 6.5]; P = .011). CONCLUSION: The G2D ePRO tool enhanced communication between patients and clinical teams, contributing to improved discharge planning and recovery. Respondents to the tool had a significantly lower risk of prolonged hospital stays after surgery. Further research is needed to refine digital discharge tools and explore strategies for optimizing recovery preparation.
- 28 June 2025
- Published by Springer Nature in Journal of Medical Systems
- Vol. 49 (1) , 1-30
A Simulation-Based Approach for Inpatient Capacity Management at a Hospital Dedicated for Cancer Treatment
This paper describes the development and application of an analytical solution to assist with inpatient flow and capacity management at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. We present a discrete-event simulation model that captures several key aspects of the complex patient flow patterns at MSKCC in the inpatient setting. The model captures the variation in admission patterns based on various patient cohorts and admit locations. The model also accounts for the variability in specialized care needs for distinct patient cohorts using categorical distributions. Durations for various patient flow states from admission till discharge are modeled as probability distributions. Key patient-and resource attributes are also incorporated to accurately capture the constraints affecting resource allocation. A comprehensive set of output metrics is used to validate the model, and to compare alternative scenarios. We present results for a scenario that tests the impact of resource allocation changes aimed at consolidating patients on certain floors based on the hospital department tasked with their inpatient care. Outputs for the scenario are compared with baseline using the following output metrics: mean bed utilization by floor, mean admit boarding times by service, proportion of home floor admissions by service, and wait times for step-down care beds. Our results show an estimated reduction in average admit wait times by 30 minutes or more across 4 inpatient services (an annual reduction of \(\sim \)116 days), with a neutral impact on other output metrics. The analysis from the scenario was utilized by hospital leadership to implement actual bed allocation changes in the hospital. The model demonstrates a structured analytical approach to evaluate the impact of strategic or tactical changes prior to implementing them in practice, specifically in an inpatient setting. It also provides the flexibility to design and test a wide variety of scenarios, and has proved its utility as a decision support tool that can be leveraged periodically by leadership at MSKCC.- 28 June 2025
- Published by Springer Nature in Journal of Medical Systems
- Vol. 49 (1) , 1-30
A Simulation-Based Approach for Inpatient Capacity Management at a Hospital Dedicated for Cancer Treatment
This paper describes the development and application of an analytical solution to assist with inpatient flow and capacity management at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. We present a discrete-event simulation model that captures several key aspects of the complex patient flow patterns at MSKCC in the inpatient setting. The model captures the variation in admission patterns based on various patient cohorts and admit locations. The model also accounts for the variability in specialized care needs for distinct patient cohorts using categorical distributions. Durations for various patient flow states from admission till discharge are modeled as probability distributions. Key patient-and resource attributes are also incorporated to accurately capture the constraints affecting resource allocation. A comprehensive set of output metrics is used to validate the model, and to compare alternative scenarios. We present results for a scenario that tests the impact of resource allocation changes aimed at consolidating patients on certain floors based on the hospital department tasked with their inpatient care. Outputs for the scenario are compared with baseline using the following output metrics: mean bed utilization by floor, mean admit boarding times by service, proportion of home floor admissions by service, and wait times for step-down care beds. Our results show an estimated reduction in average admit wait times by 30 minutes or more across 4 inpatient services (an annual reduction of \(\sim \)116 days), with a neutral impact on other output metrics. The analysis from the scenario was utilized by hospital leadership to implement actual bed allocation changes in the hospital. The model demonstrates a structured analytical approach to evaluate the impact of strategic or tactical changes prior to implementing them in practice, specifically in an inpatient setting. It also provides the flexibility to design and test a wide variety of scenarios, and has proved its utility as a decision support tool that can be leveraged periodically by leadership at MSKCC.- Open Access
- 1 July 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (7) , 1051-1059
A pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study
Objectives To develop a pre-operative tool to estimate the risk of peri-operative packed red blood cell transfusion in primary debulking surgery. Methods We retrospectively reviewed an institutional database to identify patients who underwent primary debulking surgery for ovarian cancer at a single center between January 1, 2001 and May 31, 2019. Receiver operating characteristic curve and area under the receiver operating characteristic curve (AUC) were calculated. Five-fold cross-validation was applied to the multivariate model. Significant variables were assigned a ‘BLOODS’ (BLood transfusion Over an Ovarian cancer Debulking Surgery) score of +1 if present. A total BLOODS score was calculated for each patient, and the odds of receiving a transfusion was determined for each score. Results Overall, 1566 patients met eligibility criteria; 800 (51%) underwent a peri-operative blood transfusion. Odds ratios (OR) were statistically significant for American Society of Anesthesiologists scores of 3 and 4 (OR 1.34, 95% confidence interval (95% CI) 1.09 to 1.63), pre-operative levels of cancer antigen 125 (CA125) (OR 2.43, 95% CI 1.98 to 2.99), platelets (OR 1.59, 95% CI 1.45 to 1.74), obesity (OR 0.76, 95% CI 0.60 to 0.96), presence of carcinomatosis (OR 2.45, 95% CI 1.93 to 3.11), bulky upper abdominal disease (OR 2.86, 95% CI 2.32 to 3.54), pre-operative serum albumin level (OR 0.31, 95% CI 0.24 to 0.40), and pre-operative hemoglobin level (OR 0.56, 95% CI 0.51 to 0.61). The corrected AUC was 0.748 (95% CI 0.693 to 0.804). BLOODS scores of 0 and 5 corresponded to 11% and 73% odds, respectively, of receiving a peri-operative blood transfusion. Conclusions We developed a universal pre-operative scoring system, the BLOODS score, to help identify patients with ovarian cancer who would benefit from surgical planning and blood-saving techniques. The BLOODS score was directly proportional to the American Society of Anesthesiologists score, presence of upper abdominal disease, carcinomatosis, CA125 level, and platelets level. We believe this model can help physicians with surgical planning and can benefit patient outcomes.
- 1 July 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (7) , 1051-1059
Open AccessA pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study
Objectives To develop a pre-operative tool to estimate the risk of peri-operative packed red blood cell transfusion in primary debulking surgery. Methods We retrospectively reviewed an institutional database to identify patients who underwent primary debulking surgery for ovarian cancer at a single center between January 1, 2001 and May 31, 2019. Receiver operating characteristic curve and area under the receiver operating characteristic curve (AUC) were calculated. Five-fold cross-validation was applied to the multivariate model. Significant variables were assigned a ‘BLOODS’ (BLood transfusion Over an Ovarian cancer Debulking Surgery) score of +1 if present. A total BLOODS score was calculated for each patient, and the odds of receiving a transfusion was determined for each score. Results Overall, 1566 patients met eligibility criteria; 800 (51%) underwent a peri-operative blood transfusion. Odds ratios (OR) were statistically significant for American Society of Anesthesiologists scores of 3 and 4 (OR 1.34, 95% confidence interval (95% CI) 1.09 to 1.63), pre-operative levels of cancer antigen 125 (CA125) (OR 2.43, 95% CI 1.98 to 2.99), platelets (OR 1.59, 95% CI 1.45 to 1.74), obesity (OR 0.76, 95% CI 0.60 to 0.96), presence of carcinomatosis (OR 2.45, 95% CI 1.93 to 3.11), bulky upper abdominal disease (OR 2.86, 95% CI 2.32 to 3.54), pre-operative serum albumin level (OR 0.31, 95% CI 0.24 to 0.40), and pre-operative hemoglobin level (OR 0.56, 95% CI 0.51 to 0.61). The corrected AUC was 0.748 (95% CI 0.693 to 0.804). BLOODS scores of 0 and 5 corresponded to 11% and 73% odds, respectively, of receiving a peri-operative blood transfusion. Conclusions We developed a universal pre-operative scoring system, the BLOODS score, to help identify patients with ovarian cancer who would benefit from surgical planning and blood-saving techniques. The BLOODS score was directly proportional to the American Society of Anesthesiologists score, presence of upper abdominal disease, carcinomatosis, CA125 level, and platelets level. We believe this model can help physicians with surgical planning and can benefit patient outcomes.
- 18 April 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 186, 104-109
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer
- 18 April 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 186, 104-109
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer
- 21 March 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (7) , 1098-1101
ARIA II: a randomized controlled trial of near-infrared Angiography during RectosIgmoid resection and Anastomosis in women with ovarian cancer
Background Ovarian cancer with extensive metastatic disease involving pelvic structures often requires rectosigmoid resection for complete gross resection; however, it is associated with increased surgical morbidity. There are limited data, and none in ovarian cancer, on near-infrared assessment of perfusion in rectosigmoid resections with anastomosis. Primary Objective To compare the rate of pelvic complications (pelvic abscesses, anastomotic leaks, and infections) within 30 days of surgery with and without near-infrared assessment of perfusion at time of rectosigmoid resection and re-anastomosis in patients undergoing cytoreductive surgery for ovarian cancer. Study Hypothesis We hypothesize the use of near-infrared technology (intravenous indocyanine green and endoscopic near-infrared fluorescence imaging), compared with standard intra-operative assessment, to evaluate anastomotic perfusion at time of rectosigmoid resection and re-anastomosis will result in lower rates of post-operative pelvic complications. Trial Design This is a planned multicenter randomized controlled trial. Patients who undergo rectosigmoid resection as part of their ovarian cytoreductive surgery will be randomized 1:1 to standard assessment of anastomosis with the surgeon’s usual technique (control arm) or assessment with near-infrared angiography using indocyanine green and endoscopic fluorescence imaging (experimental arm). Randomization will occur after rectosigmoid resection has been completed and the surgeon declares their plan to create a diverting ostomy. Randomization will be stratified by plan for diverting ostomy. Major Inclusion/Exclusion Criteria Main inclusion criteria include patients with primary or recurrent ovarian, fallopian tube, or primary peritoneal cancer who are scheduled for cytoreductive surgery with suspected need for low-anterior rectosigmoid resection. Primary Endpoint Rate of 30-day post-operative pelvic complications. Sample Size 310 (155 per arm) Estimated Dates for Completing Accrual and Presenting Results Q2 2027 and Q4 2027, respectively. Trial Registration NCT04878094.
- 21 March 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (7) , 1098-1101
ARIA II: a randomized controlled trial of near-infrared Angiography during RectosIgmoid resection and Anastomosis in women with ovarian cancer
Background Ovarian cancer with extensive metastatic disease involving pelvic structures often requires rectosigmoid resection for complete gross resection; however, it is associated with increased surgical morbidity. There are limited data, and none in ovarian cancer, on near-infrared assessment of perfusion in rectosigmoid resections with anastomosis. Primary Objective To compare the rate of pelvic complications (pelvic abscesses, anastomotic leaks, and infections) within 30 days of surgery with and without near-infrared assessment of perfusion at time of rectosigmoid resection and re-anastomosis in patients undergoing cytoreductive surgery for ovarian cancer. Study Hypothesis We hypothesize the use of near-infrared technology (intravenous indocyanine green and endoscopic near-infrared fluorescence imaging), compared with standard intra-operative assessment, to evaluate anastomotic perfusion at time of rectosigmoid resection and re-anastomosis will result in lower rates of post-operative pelvic complications. Trial Design This is a planned multicenter randomized controlled trial. Patients who undergo rectosigmoid resection as part of their ovarian cytoreductive surgery will be randomized 1:1 to standard assessment of anastomosis with the surgeon’s usual technique (control arm) or assessment with near-infrared angiography using indocyanine green and endoscopic fluorescence imaging (experimental arm). Randomization will occur after rectosigmoid resection has been completed and the surgeon declares their plan to create a diverting ostomy. Randomization will be stratified by plan for diverting ostomy. Major Inclusion/Exclusion Criteria Main inclusion criteria include patients with primary or recurrent ovarian, fallopian tube, or primary peritoneal cancer who are scheduled for cytoreductive surgery with suspected need for low-anterior rectosigmoid resection. Primary Endpoint Rate of 30-day post-operative pelvic complications. Sample Size 310 (155 per arm) Estimated Dates for Completing Accrual and Presenting Results Q2 2027 and Q4 2027, respectively. Trial Registration NCT04878094.
- 31 January 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (4) , 594-601
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series
Objective To evaluate the feasibility and outcomes of performing procedural interventions, defined as surgical resection, tumor ablation, or targeted radiation therapy, for oligoprogressive disease among patients with gynecologic malignancies who are treated with immune checkpoint blockade. Methods Patients with gynecologic cancers treated with immune checkpoint blockade between January 2013 and October 2021 who underwent procedural interventions including surgical resection, interventional radiology ablation, or radiation therapy for oligoprogressive disease were identified. Procedures performed before immune checkpoint therapy initiation or ≥6 months after therapy completion were excluded. Long immunotherapy duration prior to intervention was defined as ≥6 months. Progression-free survival and overall survival were calculated from procedure date until disease progression or death, respectively. Results During the study period, 886 patients met inclusion criteria and received immune checkpoint blockade therapy. Of these, 34 patients underwent procedural interventions for oligoprogressive disease; 7 underwent surgical resection, 3 underwent interventional radiology ablation, and 24 underwent radiation therapy interventions. Primary disease sites included uterus (71%), ovary (24%), and cervix (6%). Sites of oligoprogression included abdomen/pelvis (26%), bone (21%), lung (18%), distant lymph node (18%), brain (9%), liver (6%), and vagina (3%). Most tumors (76%) did not exhibit microsatellite instability or mismatch repair deficiency. Approximately half (53%) of the patients had long immune checkpoint therapy duration prior to intervention. Median progression-free survival following the procedure was 5.3 months (95% CI, 3.1–9.9), and median overall survival was 21.7 months (95% CI, 14.9–not estimable). Long versus short immune checkpoint therapy duration prior to procedure and length of immune checkpoint therapy had no effect on progression-free or overall survival. Conclusions Procedural interventions for patients with oligoprogression on immune checkpoint blockade therapy are feasible and demonstrate favorable outcomes. With expanding use of immune checkpoint therapy, it is important to investigate combined modalities to maximize therapeutic benefit for patients with gynecologic cancers.
- 31 January 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (4) , 594-601
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series
Objective To evaluate the feasibility and outcomes of performing procedural interventions, defined as surgical resection, tumor ablation, or targeted radiation therapy, for oligoprogressive disease among patients with gynecologic malignancies who are treated with immune checkpoint blockade. Methods Patients with gynecologic cancers treated with immune checkpoint blockade between January 2013 and October 2021 who underwent procedural interventions including surgical resection, interventional radiology ablation, or radiation therapy for oligoprogressive disease were identified. Procedures performed before immune checkpoint therapy initiation or ≥6 months after therapy completion were excluded. Long immunotherapy duration prior to intervention was defined as ≥6 months. Progression-free survival and overall survival were calculated from procedure date until disease progression or death, respectively. Results During the study period, 886 patients met inclusion criteria and received immune checkpoint blockade therapy. Of these, 34 patients underwent procedural interventions for oligoprogressive disease; 7 underwent surgical resection, 3 underwent interventional radiology ablation, and 24 underwent radiation therapy interventions. Primary disease sites included uterus (71%), ovary (24%), and cervix (6%). Sites of oligoprogression included abdomen/pelvis (26%), bone (21%), lung (18%), distant lymph node (18%), brain (9%), liver (6%), and vagina (3%). Most tumors (76%) did not exhibit microsatellite instability or mismatch repair deficiency. Approximately half (53%) of the patients had long immune checkpoint therapy duration prior to intervention. Median progression-free survival following the procedure was 5.3 months (95% CI, 3.1–9.9), and median overall survival was 21.7 months (95% CI, 14.9–not estimable). Long versus short immune checkpoint therapy duration prior to procedure and length of immune checkpoint therapy had no effect on progression-free or overall survival. Conclusions Procedural interventions for patients with oligoprogression on immune checkpoint blockade therapy are feasible and demonstrate favorable outcomes. With expanding use of immune checkpoint therapy, it is important to investigate combined modalities to maximize therapeutic benefit for patients with gynecologic cancers.
- Open Access
- 8 December 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (1) , 113-121
Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer
Objective We sought to investigate the safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism among women who undergo neoadjuvant chemotherapy for the treatment of advanced ovarian cancer. Methods A retrospective study using data extrapolated from a prospectively maintained institutional database was used to identify all patients with ovarian cancer who underwent neoadjuvant chemotherapy from April 2015 through September 2018 at our institution. All patients who received therapeutic anticoagulation for newly diagnosed venous thromboembolism at initial diagnosis or during neoadjuvant chemotherapy were included. Results Of 290 patients who underwent neoadjuvant chemotherapy for advanced ovarian cancer during the study period, 67 (23%) had newly diagnosed venous thromboembolism at the time of initial diagnosis or developed venous thromboembolism during neoadjuvant chemotherapy. Of these 67 patients, 64 (96%) received therapeutic anticoagulation. A total of 13 (20%) of 64 patients who underwent therapeutic anticoagulation experienced a bleeding episode while on anticoagulation; 4 (31%) of the 13 events were of major severity. Three patients developed major internal bleeding in the peritoneal cavity, and one patient suffered from a major vaginal bleeding episode. All four patients were hospitalized (range, 5–11 days) and received ≥2 units of red blood cells for anemia. None of these patients died from fatal bleeding or had to delay starting chemotherapy. Of note, all four patients received low-molecular-weight heparin via subcutaneous injection. Overall, 13 (20%) of 64 patients required an anticoagulant dose reduction, mostly due to weight loss or new bleeding episodes. Conclusion Therapeutic anticoagulation in this setting appeared safe, with a low risk of major bleeding complications. Furthermore, anticoagulation did not result in delay of chemotherapy or cytoreductive surgery.
- 8 December 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (1) , 113-121
Open AccessSafety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer
Objective We sought to investigate the safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism among women who undergo neoadjuvant chemotherapy for the treatment of advanced ovarian cancer. Methods A retrospective study using data extrapolated from a prospectively maintained institutional database was used to identify all patients with ovarian cancer who underwent neoadjuvant chemotherapy from April 2015 through September 2018 at our institution. All patients who received therapeutic anticoagulation for newly diagnosed venous thromboembolism at initial diagnosis or during neoadjuvant chemotherapy were included. Results Of 290 patients who underwent neoadjuvant chemotherapy for advanced ovarian cancer during the study period, 67 (23%) had newly diagnosed venous thromboembolism at the time of initial diagnosis or developed venous thromboembolism during neoadjuvant chemotherapy. Of these 67 patients, 64 (96%) received therapeutic anticoagulation. A total of 13 (20%) of 64 patients who underwent therapeutic anticoagulation experienced a bleeding episode while on anticoagulation; 4 (31%) of the 13 events were of major severity. Three patients developed major internal bleeding in the peritoneal cavity, and one patient suffered from a major vaginal bleeding episode. All four patients were hospitalized (range, 5–11 days) and received ≥2 units of red blood cells for anemia. None of these patients died from fatal bleeding or had to delay starting chemotherapy. Of note, all four patients received low-molecular-weight heparin via subcutaneous injection. Overall, 13 (20%) of 64 patients required an anticoagulant dose reduction, mostly due to weight loss or new bleeding episodes. Conclusion Therapeutic anticoagulation in this setting appeared safe, with a low risk of major bleeding complications. Furthermore, anticoagulation did not result in delay of chemotherapy or cytoreductive surgery.
- 22 September 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 176, S59
Patient-reported symptoms after debulking surgery and associations with urgent care visits, readmissions, and complications (161)
- 22 September 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 176, S59
Patient-reported symptoms after debulking surgery and associations with urgent care visits, readmissions, and complications (161)
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2300137
Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer
Mutations in ovarian cancer risk genes are found in women of diverse ancestries, supporting genetic testing for ALL
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2300137
Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer
Mutations in ovarian cancer risk genes are found in women of diverse ancestries, supporting genetic testing for ALL
- 9 September 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166, S237-S238
Ten-year conditional probability of survival for patients with ovarian cancer: A new metric for the new millennium (480)
- 9 September 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166, S237-S238
Ten-year conditional probability of survival for patients with ovarian cancer: A new metric for the new millennium (480)